57075-84-0

Usage

Uses

Used in Organic Synthesis:
2-Propyloxybenzamidine, Hydrochloride is used as a synthetic intermediate for the creation of a wide range of organic compounds. Its reactivity and functional groups allow chemists to employ it in the synthesis of complex molecules, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Propyloxybenzamidine, Hydrochloride is used as a key component in the development of new drugs. Its unique chemical properties enable it to be incorporated into the molecular structures of potential therapeutic agents, contributing to their overall efficacy and pharmacological properties.
Used in Research and Development:
2-Propyloxybenzamidine, Hydrochloride is also utilized in research and development settings, where it can be employed to study various chemical reactions and mechanisms. Its use in this context aids in the advancement of scientific knowledge and the discovery of novel applications in various fields, including materials science, chemical engineering, and biotechnology.

Upstream product

• 6609-58-1 2-propoxybenzonitrile 
• 97-93-8 triethylaluminum 
• 75-24-1 trimethylaluminum 

Relevant academic research and scientific papers

Novel imidazotriazinones and the use thereof

Novel imidazotrizinones of general formula (I), a method for the production and the pharmaceutical use thereof are disclosed.

2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors

The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.

7-alkyl- and cycloalkyl-substituted imidazotriazinones

The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.

2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors

2-(Sulfamoyl-substituted phenyl)-3H-imidazo (5,1-f) (1,2,4) triazin-4-ones (I) are new. Imidazotriazinones of formula (I) and their salts, N-oxides and isomeric forms are new: R1 = H or 1-4C alkyl; R2 = 1-4C straight chain alkyl; R3, R4 = H, 2-8C alkenyl, 1-8C alkoxy or 1-10C alkyl (optionally interrupted by O and/or substituted by a very wide range of specific groups); or R3 or R4 = NR20R21, adamantyl, 2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl, sulfolanyl, hydroxy-sulfolanyl, 2-oxo-tetrahydrofuran-3-yl; or 3-8C cycloalkyl, 6-10C aryl or 5-7 membered heterocycle, all optionally substituted by specific groups; or NR3R4 = (a) optionally benzo-fused, saturated, partially unsaturated or unsaturated 5-7 membered heterocycle, optionally containing 1-3 of S, N, O and NR37 and optionally substituted by a very wide range of specific groups; or (b) a group of formula (i)-(iv); R20,R21 = H or 1-6C alkyl; R37 = H, OH, CHO, CF3, up to 4C acyl, up to 4C alkoxycarbonyl, 1-4C alkoxy, 1-6C alkyl (optionally substituted by specific groups) or -(CO)iE; i = 0 or 1; E = 3-7C cycloalkyl or benzyl; 6-10C aryl or 5- or 6-membered heteroaryl, both optionally substituted by specific groups ; or 5-methyl-1-oxo-2,1,3-oxadiazol-4-yl, N-methylpiperazino or morpholino; R5,R6 = H, 1-6C alkyl, OH or 1-6C alkoxy. The full definitions are given in the DEFINITIONS (Full Definitions) field. An Independent claim is included for the preparation of (I).

1,6-Dihydro-6-oxo-2-(ortho-substituted phenyl)pyrimidine-5-carboxylic acid derivatives

A series of 1,6-dihydro-6-oxo-2-(ortho-substituted phenyl)pyrimidine-5-carboxylic acid derivatives is provided for use as inhibitors of allergic reactions. The compounds show antiallergy activity by both oral and parenteral routes of administration.